Gonadotropin-releasing hormone agonists: Strategies formanaging the hypoestrogenic effects of therapy

Judd, Howard L.

doi:10.1016/0002-9378(92)91708-i

Search citation statements

Order By: Relevance

Paper Sections

Select...

Discussion1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

1994

1997

Publication Types

Select...

Article6

Relationship

Self Cite0

Independent6

Authors

Journals

Cited by 14 publications

(1 citation statement)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In one particular study, low doses of nafarelin (200 pg/day) were associated with constant bone mineral measurements, whereas high doses (400 pg/day) revealed significant decreases in bone mineral content [5]. Prompted by the desire to modify risks, several series of pilot studies have explored the addition of progestins to the regimen [6].…”

Section: Discussionmentioning

confidence: 99%

Naf arelin in the Treatment of Endometriosis

Hull¹,

Barbieri²

1994

Gynecol Obstet Invest

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Naf arelin in the Treatment of Endometriosis

Hull¹,

Barbieri²

1994

Gynecol Obstet Invest

View full text Add to dashboard Cite

show abstract

Ipriflavone prevents the loss of bone mass in pharmacological menopause induced by GnRH-agonists

Gambacciani¹,

Cappagli²,

Piaggesi³

et al. 1997

Calcif Tissue Int

View full text Add to dashboard Cite

In a double-blind, placebo controlled study, ipriflavone (600 mg/day, T.D.D.) or identical placebo tablets were given with 500 mg/day of calcium to patients treated with the gonadotropin hormone-releasing hormone agonist (Gn-RH-A) leuproreline acetate, 3.75 mg every 30 days for 6 months. In placebo-treated subjects (n = 39), urinary hydroxyproline excretion and plasma osteocalcin levels showed a significant (P < 0.01 and P < 0.05, respectively) increase, whereas spine bone density and total body bone density significantly (P < 0.001 and P < 0.05, respectively) decreased after 3 and 6 months of GnRH-A administration. Conversely, in the ipriflavone-treated group (n = 39), no significant difference in bone markers and bone density was evidenced. These data indicate that ipriflavone can restrain the bone remodeling processes and prevent the rapid bone loss that follows medically induced hypogonadism.

show abstract

Treatment of moderate and severe hirsutism by gonadotropin-releasing hormone agonists in women with polycystic ovary syndrome and idiopathic hirsutism

Falsetti

Pasinetti

1994

Fertility and Sterility

View full text Add to dashboard Cite

Gonadotropin-releasing hormone agonists: Strategies formanaging the hypoestrogenic effects of therapy

Cited by 14 publications

References 8 publications

Naf arelin in the Treatment of Endometriosis

Naf arelin in the Treatment of Endometriosis

Ipriflavone prevents the loss of bone mass in pharmacological menopause induced by GnRH-agonists

Treatment of moderate and severe hirsutism by gonadotropin-releasing hormone agonists in women with polycystic ovary syndrome and idiopathic hirsutism

Contact Info

Product

Resources

About